Testing for DVT/PE Steve Kizer MD. Why do the strategies for testing for thromboembolic disease seem so difficult? Confusion as to the goals of treatment.

Slides:



Advertisements
Similar presentations
Investigations for PE and DVT, including sensitivity and specificity
Advertisements

Brian M. Johnson, MD CCRMC PBL 11/7/12
VTE Toolkit Chapter Five Venous Disease Coalition
Atiya Khalid GPST1 A & E;AGH. Defination: DVT is the formation of a thrombus (blood clot) in a deep vein, usually in the legs, which partially or completely.
Good Morning and Welcome Applicants!
P ULMONARY THROMBOEMBOLISM SPECIFIC SITUATIONS Dr.E.Shabani.
Diagnosing Pulmonary Embolism in 2003 Dr. Peter Jones Emergency Medicine Specialist Auckland Hospital.
The PERC Rule. The paper Kline et al Journal of Thrombosis and Haemostasis 2008 Prospective Multicenter Evaluation of the Pulmonary Embolism Rule Out.
+ Deep Vein Thrombosis Common, Preventable, and potentially Fatal.
Long-Term Outcome After Additional Catheter-Directed Thrombolysis versus Standard Treatment for Acute Iliofemoral Deep Vein Thrombosis (The CaVenT Study):
Venous Thromboembolism
Deep vein thrombosis David Hughes. Pathophysiology normal deep pelvic/leg veins thrombus (red cells, fibrin) around valves propagation Virchow’s triad.
Below the Knee DVT and Pregnancy Related Thrombosis Robert Lampman, MD Morning Report July 2009.
DPT 732 SPRING 2009 S. SCHERER Deep Vein Thrombosis.
D-dimer in the Diagnosis of Pulmonary Embolism Cheryl Pollock PGY-3.
© Siemens All rights reserved. The Clinical Utility of D-dimer Assays Beth Phillips MT,SH (ASCP) Zone Technical Application Specialist Siemens Healthcare.
Approximately 600,000 new cases are diagnosed in the U.S. each year Thrombus formation in deep veins of legs or thighs Tibial veins, soleal/gastrocnemius.
DVT: Symptoms and work-up Sean Stoneking. DVT Epidemilogy Approximately 600,0000 new cases of DVT each year 50% in hospitalized patients or nursing home.
DVT/PE/VTE Adrian Burger 26 April Virchow Triad 3 primary components: venous stasis injury to the intima changes in the coagulation properties of.
What is it? A deep vein thrombosis is a condition where the blood clots in a distal, deep vein A blood clot is considered a thrombosis as long as it is.
What You Need to Know about Blood Clots. What You Need to Know About Blood Clots or Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
Prospective evaluation of Innovance D-dimer in the exclusion of venous thromboembolism [VTE]. Robert Gosselin, CLS Department of Clinical Pathology and.
Postoperative venous thromboembolic disease prevention in the neurosurgery population Ahmad Khaldi, M.D. 1 Michael Wall, PharmD 2 T.C. Origitano, M.D.,
Case Report Pneumology Dr. David Tran A&E, FVHospital Medical meeting September 28 th, 2011.
به نام خدا. دكتر محمد امامي فوق تخصص ريه عضو هيات علمي دانشگاه.
Shortness of breath By: Tina Tarazi. Patient is a 49 year old F with PMH of NSCLC s/p chemotherapy and radiation and right frontal lobe resection in 12/2013.
Venous Thromboembolism: Diagnosis and Managament
Evidence Based Medicine Workshop Diagnosis March 18, 2010.
PULMONARY EMBOLI Kenney Weinmeister M.D.. PULMONARY EMBOLI w Over 500,000 cases per year. w Results in 200,000 deaths. w Mortality without treatment is.
+ Clinical Decision on a Diagnostic Test Inna Mangalindan. Block N. Class September 15, 2008.
Diagnosis: EBM Approach Michael Brown MD Grand Rapids MERC/ Michigan State University.
71-year old male Admitted with worsening shortness of breath PMHx: Severe COPD, A.Fib, CHF/ischemic, PE On long term anticoagulation with Pradaxa 150.
IVC filters what you need to know Sam Chakraverty Consultant Radiologist Ninewells Hospital Dundee, Scotland.
Jomo Osborne Lung-2015 Baltimore, USA July , 2015.
1. Statistics Objectives: 1.Try to differentiate between the P value and alpha value 2.When to perform a test 3.Limitations of different tests and how.
Appropriateness of PE workup at UCI based on Well’s Criteria Amy Ni, MD Cost Consciousness Project: March 2015.
PE Clinical Evaluation. Presenting Complaint Most common presenting complaint: dyspnoea Chest pain Syncope Cough Leg pain.
 Deep Vein Thrombosis Josh Vrona, Hunter Dolan, Erin McCann.
Prof. Mona Mansour Professor of Pulmonary Medicine Ain Shams University.
Excluding the Diagnosis of Pulmonary Embolism: Is There a Magic Ball? COPYRIGHT © 2015, ALL RIGHTS RESERVED From the Publishers of.
Diagnostic Test Characteristics: What does this result mean
EBM --- Journal Reading Presenter :傅斯誠 Date : 2005/10/26.
Issues in diagnosis of VTE in Pregnancy Ng Heng Joo Department of Haematology Singapore General Hospital.
Case 2: IVC Filters 44 y/o male “preaching pastor” 10/23Generalized seizure Large AVM 2/12Embolization, left frontal craniotomy and resection c/b right.
Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing June 2012 NICE clinical guideline.
Diagnosis of Deep Vein Thrombosis Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis, 9th.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
By Anthony Suminiski, Jess Stone and Mitchell Richards.
Homans Sign: A Sign of What? COPYRIGHT © 2016, ALL RIGHTS RESERVED From the Publishers of.
Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism ‘ The PADIS-PE Trial’ Nate Peyton.
Venous Thromboembolic Disease: The Role of Novel Anticoagulants Grant M. Greenberg MD, MA, MHSA.
Asad Mehdi, MD. Outline A Diagnostic Approach to Pulmonary Embolism Clinical Presentation Risk Stratification Wells Criteria Geneva Rule PIOPED Approach.
Serial 2-Point Ultrasonography Plus D-Dimer vs Whole-LegColor-CodedDopplerUltrasonography for Diagnosing Suspected Symptomatic Deep Vein Thrombosis A Randomized.
Pulmonary Embolism in Patients with Unexplained Exacerbation of COPD: Prevalence and Risk Factors Isabelle Tillie-Leblond, MD, PhD; Charles-Hugo Marquette,
Outpatient DVT assessment & treatment Daniel Gilada.
Diagnosis Recitation. The Dilemma At the conclusion of my “diagnosis” presentation during the recent IAPA meeting, a gentleman from the audience asked.
Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients Thrombosis Research (2008)
Pulmonary Embolism Presentation to Diagnosis
the proximal femoral fracture patients
Diagnosis of venous thromboembolism
The Evaluation of Suspected Pulmonary Embolism
Evidence Based and Cost Effective Guideline for DVT Triage
From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann.
Pulmonary Thrombo-Embolism
Anne Knisely, MS4 Diagnostic Radiology elective
Pulmonary Embolism Doug Bretzing, pgy 3
Refining Probability Test Informations Vahid Ashoorion MD. ,MSc,
Venous Thromboembolism (VTE)
CTA chest use in ED to fish for PEs
Calculate Well’s score for PE (BOX1)
Presentation transcript:

Testing for DVT/PE Steve Kizer MD

Why do the strategies for testing for thromboembolic disease seem so difficult? Confusion as to the goals of treatment Poor understanding of the tests Confusion by proxy

The goals of therapy By far, most patients presenting with PE are stable. For those that are critical, attention is directed to removing the embolus. But for nearly all patients, our goal is to prevent a second PE with little regard to the existing PE. In some series, 60% of those presenting with DVT will already have a PE at the time of presentation.

The Goals of therapy, (cont’d) If we can show that the deep venous system is empty, or becomes empty, then PE will not recur. (Hull & Hirsch, 1997) Calf vein thrombi (below the popliteal space) are not a cause of PE and are a risk factor for PE only if they extend proximally. Most pelvic disease will also propagate distally. In a patient suspected of PE, studies of the proximal veins are often negative because the clot has moved.

The goals of therapy, (cont’d) Therefore the goal of therapy is straightforward: If the deep venous system is empty in a patient diagnosed with PE, then we treat to assure that the venous system remains empty. If there is clot in the deep venous system, then we treat to assure that extension and embolization of existing clot is minimized. Thus, DVT and PE are the same disease.

Goals of treatment (cont’d) How certain does one have to be that a patient has DVT/PE before undertaking treatment? 90%? 60%? 30%? 10%?

The notion of thresholds There are four decision nodes for treating any disease. What happens if I DON’T treat someone with the disease? What happens if I DO treat someone with the disease? What happens if I DO treat someone who does not have the disease? What happens if I DON’T treat someone who does not have the disease?

What happens if I don’t treat someone with the disease? 10% die. Quality adjustment 0, value = 0 30% complication (SOB, post-phlebitic leg,etc) Quality adj. 0.9, value = % alive and well. QA 1.0, value = 0.6 Total quality adjusted survival 0.87 for this decision

What happens if I treat someone with the disease? Dead 0.5%, Quality adjst 0, value = 0 Complications 12% (bleeds, post-phlebitic leg, SOB, etc.) QA 0.9, value = 0.11 Alive and well 87.5%, QA 1, value = Total survival value for this decision. NET benefit of treatment – 0.87 = 0.116

What happens if I treat someone who does not have the disease? Dead 0.05%, QA 0, value = 0 Complications 5% (minor, major bleeds, etc) QA 0.9, value = Alive and well, 94.9% QA 1, value Total quality adjusted survival value of this decision = 0.994

What happens if I don’t’ treat someone and they don’t have the disease? This is the perfect decision Dead 0%, QA 0, value = 0 Complications 0%, QA 0.9, value = 0 Alive and well, 100%, QA 1.0, value = 1 Total value of this decision = 1.00 Thus, harm of treating patients who don’t have the disease 1.00 – = 0.006

Finally, the threshold Threshold defined as ratio of harm to benefit. Total harm = Total benefit = Harm/benefit (this is an odds) = 0.006/0.116 Harm/benefit (probability) = 0.006/0.122 = 0.05 or 5%. This means if the patient that I am caring for has a greater than 5% chance of DVT/PE when all is said and done, then I treat!

Now, understanding the tests Why do we test? To increase or diminish the probability of disease In many cases we test sequentially, but this demands that the tests perform independently - an unproven assumption in most cases. Nevertheless, we can probaby come close to the truth with such an assumption in DVT/PE since the tests are unrelated physiologically.

The tests Multiple slice CT (corrected for indeterminate scans) +LR 7.8 -LR 0.2 V/Q scan High prob LR 17.8, Indeterminate 1.0, Normal or near normal 0.10 D-dimer (high sens and depends on cut-off) + LR 2.4 -LR 0.10 (only useful in outpatients!!!) Compression US (symptomatic pts) +LR 24 –LR 0.06

Using the tests The purpose of testing is to get above or below the treatment threshold This requires knowing the test characteristics as in the two previous slides and: Estimating pretest probability of PE/DVT.

Well’s Rule for Pretest probability of PE, applied when the clinical complaint may be PE. Previous DVT 1.5 pts Recent hosp/leg trauma 1.5 pts Pulse > pts Clinical evidence of DVT 3 pts No other reasonable Dx 3 pts Malignancy 1 pt Hemoptysis 1 pt For a score less <1 Prob <5%, %, 7+ 70%.

Well’s rules for Pretest probability of DVT, when presenting complaint may be DVT. * May not be fully valid in primary care. Recent casting/hemiparesis 1 pt Recent surgery/hospitalization 1 pt Malignancy 1 pt Calf circumference > 3cm diff 1 pt Swelling of leg by measurement 1 pt Unilateral edema 1 pt Past hx of DVT 1 pt Unilateral swelling superficial veins 1 pt Tenderness along the venous system 1 pt Another equally likely dx -2 pts 0 or less 5% prob of DVT, %, 3+ 50%.

Using the tests. SJ 32 yo healthy woman presents to clinic with pleuritic chest pain, no fever, cough. No trauma. Exam is normal, HR 97. CXR wnl. Pretest Prob? (score?) ~30% Prob (no other dx) What test to order?

Patient SJ – Can we decrease the Probability? Pretest Prob 30%, odds 3/7 Neg D-dimer 3/7 x 0.10 = 0.30/7 odds Post test prob = 0.3/7.3 = ~5% V/Q scan (normal or near normal) 3/7 x 0.10 = 0.3/7 odds Post test prob = 0.3/7.3 = 0.04 ~ 4% Multislice CT 3/7 x 0.2 = 0.6/7 odds Post test prob = 0.6/7.6 = ~ 8% What would you order?

Pt SJ – Can we increase the probability? D-dimer 3/7 x 2.4 = 7.2/7odds Post test prob 7.2/14.2 = 0.5 ~50% V/Q scan (high prob) 3/7 x 17.8 = 53.4/7 odds Post test prob 53.4/60.4 = 0.88 = ~ 88% Multislice CT 3/7 x 7.8 = 23.4/7 odds Post test prob 23.4/30.4 = 0.77 ~77%

Unanswered questions Can patient with high probability of PE be left untreated if deep venous system is, and remains, empty by US? This has been verified as a viable strategy for those at intermediate probabilities. If so this changes strategy dramatically. Then approach to patients with PE would be to verify empty proximal veins.

Patient RJ 56 yo man, recent MVA, frx of left tibia, casted, also in hospital for 2 wks for ruptured spleen and kidney. Develops SOB, fever, HR 115. CXR clear, U/A wnl, no evidence for abdominal infection. Left leg swollen. Rt calf 31 cm left 34 cm Pretest prob? Score 4, 60% probability

Testing RJ Pretest prob is so high, that our goal is to try to reduce probability to level not requiring treatment (5%). If we cannot, then we treat. D-dimer (not useful in inpatients) V/Q (normal/near normal) 7/3 x 0.1 = 0.7/3 odds Post test prob 0.7/3.7 = 0.19 = ~19% Multislice CT 7/3 x 0.2 = 1.4/3 odds Post test prob 1.4/4.4 = 0.32 = ~32% Now what?

Thinking further about RJ Pretest probability for DVT for RJ, Wells score is 4, ~50% prob of DVT. Duplex US positive 1/1 x 25 = 25/1 odds of DVT or post test prob of 25/26 = 0.97 or 97% prob > Treat Duplex US negative 1/1 x 0.04 = 0.04/1 odds of DVT or post test prob of 0.04/1.04 = or ~4%. > No treatment. Repeat US in 1-2 weeks

Further thinking about RJ This is based on empirical trials of Hull and Hirsch that show for intermediate probability PE if the deep venous system is empty, the risk for PE (even if patient may have had one) is less than 2%.

What have we learned? Possibly nothing Make a reasonable estimate of pretest probability of disease. Then based on your knowledge of the 4 available tests, try to obtain a post test probability less than 5%. If you can, do not treat. If you cannot, then treat.

One final point The threshold will change depending on treatment risks. For example, as the risks of bleeding or complications of therapy increase, the threshold will rise. This means, if a 90 yr old man with a hx of GI bleeding 5 yrs ago is considered, the threshold may go up to 12% or more.

One final, final point Filters, removable or not are not particularly effective or durable treatments for preventing PE. If the filter cannot be removed, the risk for long term complications such as DVT of lower extremities is about 30-35% and after 9mos – 1 year, any protection afforded by the filter wanes.